News
FDA approves pomalidomide for MM
The US Food and Drug Administration (FDA) has granted accelerated approval for the immunomodulatory agent pomalidomide (Pomalyst) to treat...
News
New antihemophilic factors last longer than standard treatments
Data from the phase 3 A-LONG study indicated that patients with hemophilia A could maintain low bleeding rates with once- to twice-weekly...
News
FDA approves plasma product
The FDA has approved a pooled plasma blood product (Octaplas) that can be used to replace coagulation factors in patients with certain medical...
News
FDA approves apixaban for patients with NVAF
The agency’s decision is based on results of the ARISTOTLE trial, in which NVAF patients taking apixaban experienced fewer strokes than those on...
News
Study supports extended apixaban use
ATLANTA—Due to results of the AMPLIFY-EXTENSION study, researchers are recommending a new indication for apixaban: long-term use to prevent...
News
Findings could revolutionize malaria drug testing
Scientists have reported that injecting cryopreserved malaria sporozoites in human subjects can result in controlled infection. This indicates...
News
Factor appears safe, effective in hemophilia B
The goal of the phase 3 study, called B-LONG, was to evaluate the safety and efficacy of a long-lasting recombinant factor IX Fc fusion protein (...
News
FDA approves 3rd-generation TKI for CML
Bosutinib is intended for use in patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive CML who have failed therapy...
News
Secondary prophylaxis reduces bleeding in hemophilia
PARIS—Results of a phase 3 study indicate that the recombinant antihemophilic factor octocog alfa is effective as secondary bleeding prophylaxis...
News
Hemophilia patients plagued by professional challenges
their disorder has had a negative impact on their career. In fact, 1 in 5 patients said they have lost a job because of their condition....
News
Despite efficacy, most patients discontinued therapy
In a multicenter trial, deferasirox reduced serum ferritin and labile plasma iron (LPI) in transfusion-dependent patients with myelodysplastic...
News
Drug for aHUS effective but expensive
AMSTERDAM—Eculizumab elicits “phenomenal” results in atypical hemolytic uremic syndrome (aHUS), according to two presentations given at the 17th...
News
FDA approves drugs faster than EMA, Health Canada
The researchers say these results refute criticisms that the drug approval process in the US is slow and that agencies in other countries tend to...
News
Report reveals detailed data of ruxolitinib in MF
Ruxolitinib can ease the symptoms of myelofibrosis and improve patient survival, according to results of the COMFORT-I study. Detailed data from...